Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 308.00 shares, a 46.06% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 20.34K shares.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 42.50K shares.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 67.58K shares, a 302.27% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 16.80K shares.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 308.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 63.15K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 63.41K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 20.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 67.58K shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 42.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2025-06-30 | 571.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | |
| 2025-03-31 | 4.17K shares 10-Q · filed 2025-05-13 | |
| 2024-12-31 | 16.80K shares 10-K · filed 2026-03-27 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2025-03-31 | |
| 2022-09-30 | 127.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-12-31 | 2.91K shares 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |